Latest Veterinary Therapeutics News

Page 1 of 1

Argent BioPharma Cuts US$5.5m Debt with Splash Licensing Deal, Advances Veterinary Assets

Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.

Ada Torres

28 July 2026

Browse the archive

Full archive

Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026